A New Era of Managing Thyroid Eye Disease

Jae Hoon MoonSouth Korea Speaker A New Era of Managing Thyroid Eye Disease: AI-Based Quantitative Monitoring and Precision CareThyroid Eye Disease (TED) is the most common extrathyroidal manifestation of autoimmune thyroid dysfunction, occurring in approximately 30% to 50% of patients with Graves’ disease. While endocrinologists primarily manage thyroid dysfunction, TED can severely impact a patient’s quality of life through vision loss, diplopia, and cosmetic concerns, necessitating active early intervention. Consequently, it is crucial for clinicians to be proficient in basic TED assessments for early diagnosis; however, many endocrinologists remain unfamiliar with these evaluations, which often leads to delayed treatment. To usher in a new era of managing TED, a paradigm shift toward AI-based quantitative monitoring and precision care is explored in this session. Fundamental assessment methods, including the Clinical Activity Score (CAS), exophthalmos, and Margin-Reflex-Distance 1 (MRD1), will be introduced alongside clinical cases where AI-driven solutions provide objective and reproducible data. These cutting-edge tools go beyond simple diagnostic assistance by quantitatively tracking disease progression and treatment response, thereby facilitating highly personalized treatment plans. By integrating these innovative AI solutions, a comprehensive approach to TED management is presented, demonstrating how technology and innovation converge to solve long-standing clinical challenges and improve patient outcomes.